Active surveillance feasible for small, low-grade bladder cancer

January 11, 2018

(HealthDay)—For patients who present with small, low-grade pTa/pT1a recurrent papillary bladder tumors, active surveillance appears to be a reasonable strategy, according to a study published in the February issue of The Journal of Urology.

Rodolfo Hurle, M.B.B.S., from Humanitas Research Hospital in Milan, and colleagues conducted a prospective observational study involving with a history of pathologically confirmed stage pTa (grade 1 to 2) or pT1a (grade 2) nonmuscle . The patients had recurrent small size and number of tumors without hematuria and positive urine cytology.

The researchers found that 122 of the 625 patients with nonmuscle invasive cancer had a total of 146 active surveillance events. Of the events, 40.4 percent were deemed to require treatment after active surveillance. Patients spent a median of 11 months on active surveillance; 62.3 percent of patients remained under observation at the end of the study period. On univariate analysis, the only factor that seemed to be inversely associated with recurrence-free survival was time from the first transurethral resection to the start of active surveillance (hazard ratio, 0.99). In multivariate analysis, an association was seen with age at start (hazard ratio, 0.97) and the size of the lesion at the first transurethral resection (hazard ratio, 1.55). For each avoided transurethral bladder tumor resection, the average specific annual resource consumption savings was €1,378.

"Active might be a reasonable clinical and cost-effective strategy in patients who present with small, low-grade pTa/pT1a recurrent papillary bladder tumors," the authors write.

Explore further: Gender, BMI impact bladder perforation during resection

More information: Abstract/Full Text

Related Stories

Gender, BMI impact bladder perforation during resection

April 17, 2012
(HealthDay) -- For patients with bladder tumors, female gender, low body mass index, and tumor characteristics correlate with the risk of bladder perforation during transurethral resection, according to research published ...

Active surveillance of low-risk PMC of the thyroid proposed as first-line management

December 14, 2017
A 10-year study of more than 1,200 patients with low-risk papillary microcarcinoma (PMC) of the thyroid led researchers to conclude that close and continuous monitoring is an acceptable first-line approach to patient management ...

Low-risk bladder cancer rarely progresses to muscle invasion

March 6, 2013
(HealthDay)—Low-risk bladder cancer rarely progresses to muscle invasion but is associated with an increased risk of disease-specific mortality compared with matched populations, according to research published in the March ...

What you need to know about bladder cancer

July 26, 2016
Bladder cancer accounts for 5 percent of all new cancer diagnoses in the U.S. with nearly 77,000 new cases annually; 1,100 people died of bladder cancer in Kentucky between 2010 and 2014.

Less intense surveillance OK for some prostate cancer cases

December 23, 2016
(HealthDay)—Certain patients on active surveillance for prostate cancer may be eligible for less intensive surveillance, according to a study published in the January issue of The Journal of Urology.

Surveillance biopsy timing not tied to reclassification

April 22, 2017
(HealthDay)—Timing of the first active surveillance biopsy is not associated with increased adverse reclassification of prostate cancer, according to a study published in the April issue of The Journal of Urology.

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.